TECHNETIUM TC-99M DEPREOTIDE

First approved in 1973

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C65H96N16O12S2.Tc
Molecular Weight	1455.69
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TECHNETIUM TC-99M DEPREOTIDE

Structure Search

SMILES

[Tc].CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CC5=CC=CC=C5)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O

InChI

InChIKey=MCEOYGQHDKBYFT-KTABZWLNSA-N

InChI=1S/C65H96N16O12S2.Tc/c1-38(2)55-64(92)76-49(26-30-95-37-54(83)72-35-44(69)57(85)74-47(20-10-13-28-67)58(86)79-52(36-94)62(90)73-46(56(70)84)19-9-12-27-66)65(93)81(3)53(32-39-15-5-4-6-16-39)63(91)78-50(31-40-22-24-42(82)25-23-40)60(88)77-51(33-41-34-71-45-18-8-7-17-43(41)45)61(89)75-48(59(87)80-55)21-11-14-29-68;/h4-8,15-18,22-25,34,38,44,46-53,55,71,82,94H,9-14,19-21,26-33,35-37,66-69H2,1-3H3,(H2,70,84)(H,72,83)(H,73,90)(H,74,85)(H,75,89)(H,76,92)(H,77,88)(H,78,91)(H,79,86)(H,80,87);/t44-,46-,47-,48-,49-,50-,51+,52-,53-,55-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	Tc
Molecular Weight	98.0
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C65H96N16O12S2
Molecular Weight	1357.688
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	2
Optical Activity	UNSPECIFIED

Description
Sources: https://www.hindawi.com/journals/stni/2014/839369/
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/books/NBK215133/ | https://www.iaea.org/OurWork/ST/NE/NEFW/Technical-Areas/RRS/documents /mo99/WORKINGMATERIALSmo99CM.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27854401

Molybdenum-99 (99Mo, half-life = 66 h) is a parent radionuclide of a diagnostic nuclear isotope. It decays in technetium-99 m (half-life = 6 h), which is used in over 30 million procedures per year around the world. Between 95 and 98 percent of Mo-99 is currently being produced using highly enriched uranium (HEU) targets. Other medical isotopes such as iodine-131 (I-131) and xenon-133 (Xe-133) are by-products of the Mo-99 production process and will be sufficiently available if Mo-99 is available.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
bone problems 43 Sources: https://www.drugs.com/cons/osteolite.html	Diagnostic	Approved 8429	OSTEOLITE Approved Use Unknown Launch Date 1977
osteogenesis 43 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018035s032lbl.pdf	Diagnostic	Approved 8429	DRAXIMAGE MDP-10 Approved Use MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis. Launch Date 1978

PubMed

Title	Date	PubMed
Future of low specific activity molybdenum-99/technetium-99m generator.	2012 Oct	22642420

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:32:33 GMT 2023` Edited by `admin` on `Fri Dec 15 15:32:33 GMT 2023`
Record UNII	9M48M2SF02
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TECHNETIUM TC-99M DEPREOTIDE

Common Name

English

TECHNETIUM TC 99M DEPREOTIDE [USP IMPURITY]

Common Name

English

TECHNETIUM TC-99M DEPREOTIDE [ORANGE BOOK]

Common Name

English

TECHNETIUM TC 99M DEPREOTIDE

Common Name

English

Technetium tc 99m depreotide [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

V09IA05